ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Hua Medicine Announces 2021 Annual Results
March 17, 2022Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). -
Hua Medicine Announces 2020 Interim Results
September 09, 2021New Drug Application for a potential First in Class GKA dorzagliatin accepted by NMPA Expansion of indications for dorzagliatin strengthened R&D pipeline -
Hua Medicine raises $117.4 M funding
March 30, 2018The financing is expected to fully fund the Company through completion of its two Phase 3 trials and commercial launch in China for Dorzagliatin. -
Hua Medicine picks Hong Kong, S.A.R., China for IPO
March 12, 2018The offering could raise as much as $300 million. -
Hua Medicine of Shanghai to Raise $200M to Support Novel Diabetes Drug
January 16, 2018Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin
Pharma Sources Insight January 2025
